Vertex Pharmaceuticals Other Non-Current Assets increased by 1.6% to $1.26B in Q1 2026 compared to the prior quarter.
Significant changes may indicate shifts in accounting estimates, tax positions, or non-core asset holdings.
This category includes long-term assets that do not fit into specific classifications like PP&E or intangibles, such as...
Standard line item in most balance sheets, often labeled 'Other non-current assets'.
non_current_assets_other_assets_noncurrent| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $1.24B | $1.26B |
| QoQ Change | — | +1.6% |